What is the standard dosing protocol for NAD+?

Conventional NAD+ dosing is 100-1000 mg 1x weekly iv; daily subq at lower doses via iv/subq/intranasal/oral precursors (nr/nmn). For scheduling and cycle use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

What is the regulatory status of NAD+?

NAD+ regulatory status: Approved by various routes for various uses; mass-dose IV is off-label in the United States; WADA status not on prohibited list; research level research level investigational. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For scheduling and cycle use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

How should NAD+ be stored and reconstituted?

Lyophilised NAD+ stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

What route should I use for NAD+?

NAD+ is delivered by iv/subq/intranasal/oral precursors (nr/nmn). The intranasal route is preferred for compounds targeting the central nervous system because it bypasses the BBB via the olfactory pathway. The choice depends on target system and convenience.

Home/ Compounds/ NAD+

NAD+

Protocol

For protocol designers building NAD+ into a multi-compound regimen, the practical questions are pharmacokinetic compatibility, route compatibility, receptor non-overlap, and operational scheduling around real-world constraints (travel, meals, training). The 100-1000 mg 1x weekly iv; daily subq at lower doses dose at Hours; cellular pool dynamic half-life informs which scheduling pattern fits.

Protocol / Scheduling / Cycling Applications

Loading PhaseWeekly TimingStack SchedulingPulse StrategiesTapered Cycles

Key Takeaways

Scheduling lens: NAD+'s Hours; cellular pool dynamic half-life via iv/subq/intranasal/oral precursors (nr/nmn) places it in the multi-daily-dosing bucket.
Mechanism: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle.
Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset.
Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering.
Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.

Protocol / Scheduling / Cycling Mechanism

Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Critically, NAD+ is the substrate consumed by sirtuins (SIRT1-7) and PARPs — both depend on adequate NAD+ for their longevity- and DNA-repair-related functions. NAD+ levels decline approximately 50% from age 20 to 60. The scheduling implications cascade from this mechanism: receptor occupancy curves dictate daily timing, downregulation kinetics dictate cycle length, route compatibility dictates stack scheduling. The subsections address each in turn for NAD+.

Cycle length and off-cycle planning

Standard NAD+ cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.

Travel, schedule shifts, and continuity

Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any NAD+ protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most NAD+ schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.

Daily and weekly timing

NAD+ with a Hours; cellular pool dynamic half-life pharmacokinetic profile sits in the multiple-daily-dosing bucket. The schedule is best built around either 1x weekly IV; daily SubQ at lower doses, with consistency mattering more than the absolute clock time of any single dose.

Protocol / Scheduling / Cycling Applications

Protocol Calendar

For protocol calendar scheduling, NAD+ is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Storage During Cycle

Schedule design for NAD+ in storage during cycle starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Maintenance Phase

The most-asked scheduling question for NAD+ in maintenance phase is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Off-Time

For off-time scheduling, NAD+ is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	IV	100-1000 mg	8–12 weeks on / 4 weeks off
Conservative starter	IV	60-1000 mg	4–6 weeks initial cycle
Protocol focus	IV	100-1000 mg	1x weekly IV; daily SubQ at lower doses
Maintenance phase	IV	70-1000 mg	Ongoing with periodic pauses

Dose timing for NAD+ is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

NAD+ stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.

NAD+ + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with NAD+'s mechanism in protocol / scheduling / cycling protocols.
NAD+ + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with NAD+'s mechanism in protocol / scheduling / cycling protocols.
NAD+ + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with NAD+'s mechanism in protocol / scheduling / cycling protocols.
NAD+ + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with NAD+'s mechanism in protocol / scheduling / cycling protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Approved by various routes for various uses; mass-dose IV is off-label

Flushing common with IV (rate-dependent). Mild GI upset. Pretreatment with niacinamide can reduce flush.

Lens-specific safety considerations for protocol / scheduling / cycling use of NAD+: Flushing common with IV (rate-dependent). Mild GI upset. Pretreatment with niacinamide can reduce flush. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

NAD+ metabolism in health and disease

PMID 31738478

Supporting

NAD+ decline with aging and supplementation

PMID 31197173

NAD+ vs Related Peptides

Compound	Profile	Onset	Best For
NAD+	Pyridine nucleotide cofactor	Hours; cellular pool dynamic	Protocol
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

Best practice for re-cycling?

Run baseline labs before each cycle. Compare to prior cycle. Adjust dose downward if response is maintained; adjust upward only if response is incomplete and labs support the safety margin. Long-term cycle records inform protocol drift over years.

Cycle length and off-cycle period?

Standard cycle for NAD+ is 8–12 weeks on, 4 weeks off. Longer cycles produce diminishing returns and increased downregulation risk; shorter cycles undershoot the response window. The 4-week off-period is functionally required for receptor reset rather than optional.

What if I miss a dose?

Single missed doses are not consequential for most peptide schedules. Resume the next scheduled dose; do not double-dose. Multiple consecutive missed doses (3+) effectively start an off-period and warrant re-evaluating cycle progress before resuming.

Stack timing relative to training and meals?

Fasted dosing for GH-axis and AMPK-engaging compounds; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it. Training-day-only versus daily dosing depends on the compound and the volume of training; verify against the specific protocol.

What does NAD+ stack well with?

For protocol / scheduling / cycling protocols, NAD+ pairs with compounds on complementary pathways: BPC-157, TB-500, Ipamorelin. These pairings are selected because they engage independent receptor systems from NAD+'s primary mechanism (Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle), producing additive or synergistic effects rather than receptor competition.

How does NAD+'s half-life affect dosing?

NAD+ has a plasma half-life of Hours; cellular pool dynamic, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 1x weekly iv; daily subq at lower doses dosing at 100-1000 mg per dose explains the typical onset timeline for scheduling and cycle endpoints.

Clinical Protocol

Start a NAD+ Protocol

Alukard provides physician-supervised peptide protocols with GMP-certified NAD+ and GMP-certified compounds with personalised cycle design.

Get Protocol

Quick Facts

Molecular weight: 663 Da
Half-life: Hours; cellular pool dynamic
WADA: Not on prohibited list
FDA: Approved by various routes for various uses; mass-dose IV is off-label

Stack Partners

BPC-157

TB-500

Ipamorelin

CJC-1295 without DAC (Mod GRF 1-29)

Semax

Research Note

All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for NAD+ unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised peptide protocols

Start Your Protocol / Scheduling / Cycling Protocol for NAD+

Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised